These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30232801)

  • 21. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D; Frankel AE
    J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
    Sato M; Uhara H; Koga H; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
    [No Abstract]   [Full Text] [Related]  

  • 23. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland.
    Dolaghan MJ; Oladipo B; Cooke CA; McAvoy CE
    Eye (Lond); 2019 Oct; 33(10):1670-1672. PubMed ID: 31114029
    [No Abstract]   [Full Text] [Related]  

  • 24. Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.
    Gambichler T; Stockfleth E; Susok L
    J Immunother Cancer; 2018 Oct; 6(1):113. PubMed ID: 30376886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
    Latchman J; Guastella A; Tofthagen C
    Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
    Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
    JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
    [No Abstract]   [Full Text] [Related]  

  • 27. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 28. Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.
    Maeda T; Hiura A; Uehara J; Toyoshima R; Nakagawa T; Yoshino K
    Eur J Dermatol; 2021 Oct; 31(5):662-664. PubMed ID: 34642136
    [No Abstract]   [Full Text] [Related]  

  • 29. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
    N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
    [No Abstract]   [Full Text] [Related]  

  • 30. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
    Trinh B; Sanchez GO; Herzig P; Läubli H
    J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients.
    Patel AS; Snook RJ; Sehdev A
    Discov Med; 2019 Aug; 28(152):107-111. PubMed ID: 31926582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
    Meti N; Petrogiannis-Haliotis T; Esfahani K
    J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
    [No Abstract]   [Full Text] [Related]  

  • 34. Diplopia and Acute Vision Loss After Nivolumab Plus Ipilimumab Therapy.
    Tambe A; Basnet A; Tambe V; Badrinath M; Mandru R
    Am J Ther; 2020 Sep; 28(2):e246-e247. PubMed ID: 33687029
    [No Abstract]   [Full Text] [Related]  

  • 35. Immune checkpoint inhibitors-related orchitis.
    Brunet-Possenti F; Opsomer MA; Gomez L; Ouzaid I; Descamps V
    Ann Oncol; 2017 Apr; 28(4):906-907. PubMed ID: 28039179
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 38. Enteritis with immune checkpoint inhibitor use.
    Sanders D; Webber D; Chatur N
    CMAJ; 2019 Oct; 191(40):E1106. PubMed ID: 31591098
    [No Abstract]   [Full Text] [Related]  

  • 39. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 40. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
    Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
    J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.